Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677843 | 0.92 | LOXL2 (0.54) | SLC6A2SLC6A4SLC6A3LOXL2CYP3A4 | |
| SCHEMBL516032 | 0.87 | EPHX1 (0.56) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 | |
| SCHEMBL6563096 | 0.83 | EPHX1 (0.56) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 | |
| SCHEMBL1677870 | 0.80 | LOXL2 (0.46) | SLC6A2SLC6A4SLC6A3LOXL2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29821862 | 0.78 | LOXL2 (0.45) | SLC6A2SLC6A4SLC6A3LOXL2CYP3A4 | |
| SCHEMBL2604897 | 0.75 | TAAR1 (0.50) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 | |
| SCHEMBL353179 | 0.75 | TRPA1 (0.50) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 | |
| SCHEMBL4049046 | 0.75 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP3A4ALDH1A1 | |
| SCHEMBL11517810 | 0.75 | EPHX1 (0.48) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 | |
| SCHEMBL353629 | 0.75 | EPHX1 (0.48) | SLC6A2SLC6A4SLC6A3LOXL2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| CN-1324012-C | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| CN-1590375-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| CN-1590374-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| CN-1432000-A | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | SLC6A2 3048/4885SLC6A4 1037/4885SLC6A3 2718/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | SLC6A2 3467/4885SLC6A4 1398/4885SLC6A3 2815/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | SLC6A2 3571/4885SLC6A4 1435/4885SLC6A3 2577/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | SLC6A2 4170/4885SLC6A4 2108/4885SLC6A3 3037/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | SLC6A2 4179/4885SLC6A4 2110/4885SLC6A3 3096/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | SLC6A2 3918/4885SLC6A4 2243/4885SLC6A3 3337/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | SLC6A2 3611/4885SLC6A4 3874/4885SLC6A3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.